Evaluation of Moringa Peregrina (Forsk) Fiori, Leaf and Seed Extract Against Multidrug Resistant Strains of Bacteria and Fungus of Clinical Origin

The emergence of antibiotic resistant microorganism strains has become a critical concern in the treatment infectious diseases and makes search an alternative therapy must. study was designed to evaluate vitro antimicrobial activities Moringa peregrina (MP) leave (MPL) seed (MPS) extracts. Antimicrobial assays were performed using microplate growth inhibition assay against 11 multidrug-resistant (MDR) strains. Following qualitative analysis, dose-response MTT colorimetric assay. results showed strong correlation between MPL MPS extract concentration (P<0.001). MP revealed remarkable effect inhibited survival MDR pathogens which include Escherichia coli; Pseudomonas aeruginosa; Klebsiella pneumonia; Acinetobacter baumannii; Staphylococcus aureus (88.6-94.7 %) (62.3- 88.7%) Candida Kefyer; parapsilosis; albicans; glabrata; Aspergillus flavus Fusarium oxysporum. MIC50 ranging from ≤6.25 25 mg/mL. baumannii aeruginosa most susceptible extracts (MIC50 < 6.25 mg/mL). These support use Arab traditional medicine as natural agents. Additionally, such naturally occurring adjuvant derived medicinal plants can be used with synthetic antibiotics combat bacterial resistance enhance antibacterial potential. Further studies are recommended on isolation purification novel molecules treat infections caused by microbes.